Ropes & Gray along with Cooley LLP advised on the Novo Nordisk–Vivtex $2.1 billion partnership to develop oral biologic medicines.
Novo Nordisk has entered into a partnership agreement with Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated comorbidities.
Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk and is eligible to receive upfront consideration, research funding and milestone payments totaling up to $2.1 billion, as well as tiered royalties on future product sales. Following research and formulation selection, Novo Nordisk will assume responsibility for global development, regulatory activities, manufacturing, and commercialization of any resulting products.
The collaboration aims to enable oral delivery of biologic drug candidates that are traditionally limited to injectable administration due to poor gastrointestinal absorption, combining Novo Nordisk’s expertise in peptide and protein therapeutics with Vivtex’s proprietary gastrointestinal screening and formulation platform.
Ropes & Gray LLP advised Novo Nordisk on the partnership agreement.
The Ropes & Gray team was led by life sciences licensing Partner Hannah England and Associate Ian Nilsen.
Cooley LLP advised Vivtex on the transaction.
A cross-office life sciences Partnering team of Christophe Beauduin and Jameson Davis led the Cooley team, with support from Ritu Gupta.
The deal reporting on this platform is based on the information received from law firms, and therefore, some details may be missing/incomplete. If your firm has not been credited for this deal, write to us at chanchal.makhija@thegreymatter.co.in mentioning your firm’s name, lawyers involved (including designation) and client represented.
